Shares of General Electric (GE), which has been down over 50% since last year, rebounded slightly after the company announced plans to spin off its healthcare and power subsidiaries. Meanwhile, analysts are expecting an outperformance from the stock in the near-future after the separation.
Last week, the industrial conglomerate announced its intention to spin-off its healthcare unit and detach its 62.5% investment in Baker Hughes (BHGE) in an orderly manner over the next two to three years. GE’s spotlight will turn to aviation, power and renewable energy businesses. GE projects that it will retain its current quarterly dividend until GE Healthcare is incorporated as an independent entity.
GE Healthcare’s board is expected to adjust the dividend with a policy in line with industrial peers. In addition, GE plans to substantially diminish the balance sheet of GE Capital. The company is assuming about $3 billion capital contribution to GE Capital in 2019. Following the announcement, the company’s shares rose 7.8% on June 26.
Analysts are expecting an outperformance from the stock in the near-future after the separation
Meanwhile, a few brokerage firms including JP Morgan has advised investors to sell their stake in GE due to significant overvaluation, adding that business trends are not likely to improve next year. General Electric will voluntarily lower its dividend in the future, an analyst at JP Morgan told CNBC.
Meanwhile, a majority of the sell-side analysts are expecting the company to outperform once the separation is completed. This can be known from the recommendation trends wherein seven of the 17 analysts are recommending a “strong buy” or “buy” rating, while six are maintaining a “hold” rating.
The company is scheduled to report its second-quarter earnings on July 20 before the market opens. While GE recorded a 14% growth in adjusted earnings for the first quarter, Wall Street analysts estimate a 39.30% drop in earnings in the second quarter.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on